Introducing our NEW C-C Cross Coupling Course

As part of our commitment to provide chemists with a comprehensive toolbox of important synthetic reactions, we have just introduced a new online course focusing on both traditional and cutting-edge methodology used in carbon–carbon (C–C) bond-forming reactions. Figure 1, complied by Neufeldt et al, shows the long and twisted road to development of the technologies we now take for granted.¹ Throughout this course, participants will gain not only a deep theoretical understanding but also the practical tools needed to design, troubleshoot, and optimize C–C bond-forming reactions in a variety of synthetic contexts. We’ve collated relevant academic and industrial literature, experimental details and case studies, looking at the pros and cons and highlights from detailed published studies to aid learning. Case studies are an essential part of the course and in this post we’ve highlighted an excellent example.²

Figure 1: Timeline of selected research themes in C-C cross- coupling

The ability to form robust C(sp²)–C(sp³) bonds remain an essential tool for the pharmaceutical and agrochemical industries, particularly for building three-dimensional, saturated molecules that enhance drug-like properties such as aqueous solubility, bioavailability, and metabolic stability. While modern synthetic organic chemistry has delivered many methods for constructing these bonds, their translation into practical, scalable, and reliable processes within medicinal chemistry workflows has been bumpy. This study by Dombrowski et al at AbbVie addresses a critical bottleneck in the deployment of C(sp²)–C(sp³) cross-coupling reactions by providing a systematic, head-to-head comparison of seven contemporary methods using high-throughput parallel library synthesis—a format representative of real-world medicinal chemistry demands and a screening concept used in process development to discover optimum conditions for a particular C-C coupling reaction (Figure 2).

Figure 2: C-C bond forming approaches

Over-reliance on a narrow set of transformations, notably amide bond formation, Suzuki–Miyaura C(sp²)–C(sp²) couplings, and Buchwald–Hartwig C–N couplings, has led to reduced structural diversity in compound libraries.³ Introducing sp³ centres via direct C(sp²)–C(sp³) couplings represents a strategy to counteract this trend. However, process chemists recognize that published methodologies often fail to translate to the complex, functional group-rich substrates encountered in drug discovery and development.

Furthermore, traditional approaches to incorporating alkyl groups onto (hetero)aryl motifs often require multistep sequences—e.g., vinyl coupling followed by hydrogenation—that are poorly suited to the rapid design–synthesis–test (DST) cycles demanded by pharmaceutical R&D. Hence, the comparison of direct, one-step aryl–alkyl couplings within a library synthesis context, as presented in this paper, provides valuable data on method robustness, substrate scope, and operational simplicity, directly addressing key process development concerns.

The authors evaluated seven C(sp²)–C(sp³) coupling strategies, chosen based on commercial reagent availability, mechanistic diversity, and preliminary internal experience with AbbVie (Figure 2). These included:

1. Pd-catalysed Suzuki coupling with alkyl potassium trifluoroborate (BF₃K) salts
2. Pd-catalysed Suzuki coupling with N-methyliminodiacetic acid (MIDA) boronates
3. Pd-catalysed Negishi coupling using organozinc reagents
4. Ni-catalysed reductive cross-electrophile coupling (CEC) with alkyl bromides
5. Ni/photoredox dual catalysis with alkyl BF₃K salts
6. Ni/photoredox decarboxylative coupling from alkyl carboxylic acids
7. Ni/photoredox cross-electrophile coupling with alkyl bromides

Figure 3: Coupling methods used

From a process standpoint, each method varies in terms of scalability, handling of air/moisture-sensitive reagents, reaction complexity, and by-product profiles—all critical factors for route selection and process optimisation.

The experimental workflow mirrored conditions typical of early-phase medicinal chemistry: parallel synthesis using minimal reaction conditions, automated liquid handling, reverse-phase HPLC purification, and limited optimization to reflect real-world constraints.

A total of 29 alkyl building blocks were tested across four medicinally relevant aryl bromides, with building blocks selected for steric, electronic, and functional group diversity, including primary, secondary, tertiary, benzylic, heteroatom-substituted, and cyclic systems. Library sizes varied from 13 to 41 per method, generating a comprehensive dataset of 658 reactions (Figure 4).

Reagent and Substrate availability on small scale gave the following results

• Commercial availability was highest for alkyl bromides (CEC methods) and BF₃K salts (Suzuki/photoredox).
• MIDA boronates (developed by Mark Burke in the early 2000’s) suffered from limited reagent diversity, restricting practical use.
• Organozinc reagents required for Negishi coupling were commercially available for simple substrates but necessitated in situ generation for more complex or sensitive systems, complicating scalability but not making it prohibitive.

Screening experiments revealed that 50% reaction success rate (≥10% yield) was achieved across all methods—a figure comparable to C–N couplings, validating the relevance of these reactions for practical medicinal chemistry applications. No single method universally excelled; rather, complementary strengths emerged based on alkyl group identity.

Suzuki BF₃K coupling provided good yields and broad scope for primary alkyl groups, representing a robust, scalable, and operationally simple process for installing simple saturated moieties. Negishi coupling showed excellent reactivity, albeit at the cost of increased reagent preparation complexity and handling of air-sensitive intermediates.

Ni/photoredox BF₃K coupling and Ni-catalysed CEC (both reductive and photoredox variants) enabled reliable secondary alkyl incorporation. Negishi coupling unexpectedly outperformed expectations for secondary alkyl groups, though scale-up challenges linked to organozinc reagent preparation is mentioned above.

Tertiary alkyl groups were challenging, with tert-butyl or other tertiary groups underscoring a significant gap for process chemists and a target for future methodology development.

Benzylic groups coupled efficiently via Negishi, Suzuki BF₃K, and Ni/photoredox BF₃K methods; however, sterically hindered benzylic substrates (e.g., α-methylbenzyl) were only accessible via Negishi coupling.

Figure 4: Alkyl and aryl coupling partners

Installation of polar groups (ethers, protected amines) was variable. Ni/photoredox BF₃K coupling tolerated α-heteroatom functionality, including oxetanes and tetrahydropyran systems. Decarboxylative methods selectively installed α-amino and α-oxy substituents but struggled with distal polarity. CEC methods under both photoredox and reductive conditions handled protected cyclic amines well but were limited by instability or availability of α-heteroatom alkyl bromides.

In addition to the primary coupling reaction, operational and by-product considerations are also important. Ni-catalysed radical pathways occasionally led to dehalogenation and Minisci-type byproducts, particularly with electron-deficient aryl bromides. This behaviour highlights potential scalability and purification challenges for process chemists using radical-based methods on sensitive or highly functionalized intermediates. The Suzuki BF₃K method and Negishi coupling were cleaner in this regard, favouring their consideration for scale-up when applicable. A summary of the pros and cons of each methos highlighted in the paper is shown below (Table 1).

Table 1: comparative efficiencies in cross-coupling methods

From a process chemistry perspective, the comparative study provides some useful insights:

• For early-stage parallel library synthesis, methods with broad reagent availability and minimal byproducts—e.g., Suzuki BF₃K and Ni/photoredox BF₃K couplings—are preferred.
• When secondary alkyl groups or polar functionalities are critical, photoredox BF₃K or decarboxylative strategies offer viable, albeit complex, options requiring specialized equipment (e.g., LED arrays).
• CEC methods (both photoredox and reductive) excel where reagent availability and functional group tolerance intersect, making them attractive for library production and potential scale-up, provided radical pathways are controlled.

From a green and sustainability perspective the organozinc-based Negishi coupling provides high yields for structurally diverse alkyl groups but poses logistical challenges due to reagent sensitivity and in situ preparation. Ni/photoredox methodologies require additional infrastructure (light sources, photoreactors) and control of side reactions, representing a trade-off between synthetic versatility and process complexity.

Future developments will undoubtably focus heavily on tertiary alkyl installation and remains a significant unmet need in scalable C(sp²)–C(sp³) couplings. In addition, expanded availability of building blocks (Boronic acids, MIDA boronates, specialized carboxylic acids etc.) would enhance method generality. Radical-based by-product formation highlights the need for rigorous reaction condition control and purification process development, especially for scale-up.

The AbbVie study provides a realistic, data-driven guide for medicinal and process chemists aiming to expand the C(sp²)–C(sp³) coupling toolkit. Overall, the findings encourage broader adoption of modern C(sp²)–C(sp³) couplings within medicinal chemistry, while equipping process chemists with critical knowledge to guide reaction selection, troubleshooting, and route optimization for scalable, structurally diverse small molecule synthesis.

If you’ve found this short case-study interesting, please find additional details on our C-C coupling course on our website (https://www.scientificupdate.com/training_courses/carbon-carbon-bond-formation-in-organic-synthesis-methodology-troubleshooting-and-industrial-application/)
This course is also available ‘in-house’ if you’d like to invest in your team and have this training provided on-site at a time to suit you. For more information, please contact: [email protected]

• From established to emerging evolution of cross-coupling reactions: S. Neufeldt et al, J. Org. Chem. 2024, 89, 16065–16069
• Expanding the medicinal chemist toolbox: comparing seven c(sp²)–c(sp³) cross-coupling methods by library synthesis: A. Dombrowski et al, ACS Med. Chem. Lett.2020, 11, 597–604
• Escape from flatland: increasing saturation as an approach to improving clinical success: F. Lovering et al, J. Med. Chem. 2009, 52, 6752–6756; Escape from flatland 2: complexity and promiscuity: Lovering Med. Chem. Commun. 2013, 4, 515-519